To improve the efficacy of cancer immunotherapies, ICIs (anti-PD-1/PD-L1 and anti-CTLA-4) and newer monoclonal antibody drugs(inhibiting TIGIT, TIM-3, LAG-3, VISTA, NKG2A and others) are tried in combination (6, 7). The gene discussed is CD274; the disease is cancer.